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ABSTRACT
Background: The consumption of sugar-sweetened beverages
(SSBs), which has increased substantially during the last decades,
has been associated with obesity and weight gain.
Objective: Common genetic susceptibility to obesity has been
shown to modify the association between SSB intake and obesity
risk in 3 prospective cohorts from the United States. We aimed to
replicate these findings in 2 large Swedish cohorts.
Design: Data were available for 21,824 healthy participants from
the Malmo¨ Diet and Cancer study and 4902 healthy participants
from the Gene-Lifestyle Interactions and Complex Traits In-
volved in Elevated Disease Risk Study. Self-reported SSB intake
was categorized into 4 levels (seldom, low, medium, and high).
Unweighted and weighted genetic risk scores (GRSs) were con-
structed based on 30 body mass index [(BMI) in kg/m2]-associated
loci, and effect modification was assessed in linear regression
equations by modeling the product and marginal effects of the
GRS and SSB intake adjusted for age-, sex-, and cohort-specific
covariates, with BMI as the outcome. In a secondary analysis,
models were additionally adjusted for putative confounders (total
energy intake, alcohol consumption, smoking status, and physical
activity).
Results: In an inverse variance-weighted fixed-effects meta-
analysis, each SSB intake category increment was associated with
a 0.18 higher BMI (SE = 0.02; P = 1.7 3 10220; n = 26,726). In
the fully adjusted model, a nominal significant interaction be-
tween SSB intake category and the unweighted GRS was observed
(P-interaction = 0.03). Comparing the participants within the top
and bottom quartiles of the GRS to each increment in SSB intake
was associated with 0.24 (SE = 0.04; P = 2.9 3 1028; n = 6766)
and 0.15 (SE = 0.04; P = 1.3 3 1024; n = 6835) higher BMIs,
respectively.
Conclusions: The interaction observed in the Swedish cohorts is
similar in magnitude to the previous analysis in US cohorts and
indicates that the relation of SSB intake and BMI is stronger in
people genetically predisposed to obesity. Am J Clin Nutr
2016;104:809–15.
Keywords: sugar-sweetened beverage, genetic risk score, BMI,
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INTRODUCTION
Easy access to energy-dense foods is a contributing factor to
the ongoing global obesity epidemic. According to the National
Health and Nutrition Examination Survey, the single largest
source of added sugar in the US diet today comes from sugar-
sweetened beverages (SSBs)12 (1). Epidemiologic studies, in-
cluding clinical trials, have found SSB intake to be associated
with obesity, cardiovascular disease, and type 2 diabetes (2, 3).
There is to date no clear consensus about the relation between
the consumption of artificially sweetened beverages (ASBs) and
risk of obesity and cardiometabolic diseases (4, 5).
Obesity risk is also partly attributable to genetics, and although
it is plausible that environmental factors might interact with
genetic predisposition to modify the risk, only a few examples
have so far been verified in independent cohorts (6). In a study by
Qi et al. (7) that included 3 large prospective US cohorts of
European ancestry, the association between SSB intake, but not
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ASB intake, and obesity risk was significantly more pronounced
among participants with a high genetic predisposition to obesity.
The aim of this study was to replicate the interaction reported
by Qi et al. and to investigate whether the risk of obesity as-
sociated with SSB (and ASB) intake is modified by common
genetic predisposition to obesity in 2 large Swedish cohort
studies of middle-aged participants: MDCS (Malmo¨ Diet and
Cancer Study) and GLACIER (Gene-Lifestyle Interactions and
Complex Traits Involved in Elevated Disease Risk).
METHODS
Study participants and data collection
MDCS
MDCS is a prospective cohort study that was conducted in the
city of Malmo¨ in southern Sweden and has been described in
detail elsewhere (8). All men born between 1923 and 1945 and
all women born between 1923 and 1950 were invited via per-
sonal letters and advertisements in local newspapers and public
places. Clinical characteristics, biomedical measures, and ex-
tensive information on lifestyle behaviors were collected (8),
and baseline examinations were performed between 1991 and
1996. Participants with complete dietary data, genetic information,
and without prevalent diabetes, cardiovascular disease, and cancer
were eligible for this analysis (n = 21,824). All participants pro-
vided written informed consent, and the ethics committee at Lund
University approved the MDCS protocols.
GLACIER
GLACIER is a population-based prospective cohort comprising
w19,000 initially nondiseased adults living in the county of
Va¨sterbotten in northern Sweden nested within the Northern
Sweden Health and Disease Study (9, 10). Clinical characteristics,
biomedical measures, and extensive information on lifestyle be-
haviors were obtained as part of a population-wide health screening
initiative called the Va¨sterbotten Health Survey (also called the
Va¨sterbotten Intervention Program), in which habitants in the
county of Va¨sterbotten are invited to attend an extensive health
examination the year of their 40th, 50th, and 60th birthdays (9). The
total number of GLACIER participants with genotype and pheno-
type data available for this analysis was 4902, of whom the vast
majority were born between 1932 and 1957. Baseline examinations
were performed between 1991 and 2007. All participants pro-
vided written informed consent, and the regional ethical re-
view board in Umea˚ approved all aspects of the study.
Anthropometric measures
In both MDCS and GLACIER, weight was measured with the
use of a calibrated balance-beam scale with participants wearing
light clothes and no shoes. Height (to the nearest centimeter) was
measured with a stadiometer, and BMI (in kg/m2) was calculated.
Diet and lifestyle measurements
MDCS
Diet data were collected with a modified diet history method
specifically designed for MDCS (11) that includes 1) a 7-d
menu booklet for registering cooked meals and cold beverages;
2) a 168-item food-frequency questionnaire (FFQ), including
portion sizes of regularly consumed foods not covered by the
menu book; and 3) a 45-min interview with additional questions
about the cooking methods and product choices (conducted
approximately 10 d after the clinical measurements were taken).
A trained interviewer ensured that the reporting in the ques-
tionnaire and the 7-d menu booklet did not overlap. Mean daily
food intake (g/d) was calculated based on the FFQ and 7-d menu
booklet. The MDCS database, which mostly contains data from
the PCKOST2-93 database from the National Food Adminis-
tration in Uppsala, Sweden, was used to convert reported food
intake into energy and nutrient information. A variable was
created to indicate the season of data collection [winter
(December–February), spring (March–May), summer (June–
August), and fall (September–November)] and was included as
a covariate in the analysis to adjust for potential seasonal con-
founding of the dietary intake. The diet assessment method was
also included as a covariate and was defined as data collection
before or after a minor change of coding routines implemented
in September 1994.
Leisure-time physical activity was assessed by estimates
of the number of minutes per week spent on 17 different ac-
tivities. The duration was multiplied with an activity-specific
intensity coefficient, and an overall leisure-time physical ac-
tivity score was created (12, 13). Smoking status was defined
as current smokers (including irregular smokers), former smokers,
and never smokers. Based on the participant’s reported intake
during the previous year, alcohol consumption was catego-
rized as zero (no consumption), low (,15 g/d for women
and ,20 g/d for men), medium (15–30 g/d for women and 20–
40 g/d for men), and high (.30 g/d for women and .40 g/d
for men).
GLACIER
Information on diet was collected through a self-administered
validated semiquantitative FFQ that was completed during the
visit at the primary health care center (14). The FFQ initially
covered 84 food items but was reduced in 1996 to 66 food items by
combining several questions related to similar foods. The mean
portion size of main protein sources (meat/fish), vegetables, and
staple foods (potatoes/rice/pasta) were collected, and participants
indicated how often they consumed various foods and beverages
over the past year based on a 9-point frequency scale ranging from
never to $4/d. Total energy intake was calculated based on the
nutritional values available through the National Food Admin-
istration’s database. Food intake level (total energy intake di-
vided by estimated basal metabolic rate) was used to exclude
participants with unreliable diet data. (The bottom 5% and
top 1% of the food intake level distribution within the entire
Va¨sterbotten Health Survey population was excluded.) Alcohol
consumption was quantified as g/d.
A modified version of the International Physical Activity
Questionnaire was used to gather information on leisure-time
physical activity for the past 3 mo categorized as never, occa-
sionally (not regularly), 1–2 times/wk, 2–3 times/wk, or .3
times/wk. For the current analysis, categories were combined
into a low (,1 time/wk) and a medium/high-leisure time physical
activity level ($1–2 times/wk). Smoking status was categorized
as never, former, or current.
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Intake of SSB and ASB
MDCS
SSBs include all carbonated and noncarbonated beverages
sweetened with energy-containing sweeteners (mainly sugar).
Juice was not included. ASBs include all beverages with non-
energy artificial sweeteners such as sodas, pops, and other fruit
drinks. One serving was defined as 250 g, and reported SSB and
ASB intake was converted from g/d to servings/d and further
categorized into 4 categories of intake: the first category con-
tained individuals that did not report any SSB or ASB intake
during the 7-d record (seldom consumers). The remaining par-
ticipants were divided into tertiles of SSB intake (low, medium,
and high). SSB and ASB intake were also dichotomized by
combining the first 2 and last 2 categories.
GLACIER
In the initial FFQ version (covering 84 food items), SSB intake
was covered by 2 questions—one on the intake of carbonated
(sodas) and another on noncarbonated (e.g., nectar and syrups)
SSBs that were combined into one variable for this analysis.
After 1996, the FFQ was reduced, and the 2 questions covering
SSB intake were combined into one that additionally included
juice intake. In sensitivity analyses, excluding SSB intake as-
sessed by the shorter FFQ (n = 1355) did not materially change
how the results were interpreted. This analysis thus contained
SSB intake assessed by both FFQ versions, and all models were
additionally adjusted for a variable indicating FFQ version.
For this study, the 9-level frequency scale of the FFQ (never,
occasionally, 1–3 times/mo, 1 time/wk, 2–3 times/wk, 4–6
times/wk, 1 time/d, 2–3 times/d, $4 times/d) was combined into
4 categories of intake (seldom, #2 times/y; low, 1–3 times/mo;
medium, 1–3 times/wk; and high, $4 times/wk) to reflect the
ranges within the 4 categories of SSB intake in MDCS. A di-
chotomized variable was constructed by combining the first 2
and last 2 categories (equivalent to #1–3 times/mo or $1–3
times/wk). No information on ASB consumption was available
in GLACIER.
Genotyping
MDCS
DNA was extracted from whole-blood samples with the use
of Qiagen Maxipreps. Genotyping was performed with the use
of a Sequenom MassArray matrix-assisted laser desorption/
ionization-time-of-flight mass spectrometer that used Seque-
nom reagents and protocols. Single-nucleotide polymorphisms
(SNPs) that failed Sequenom genotyping were genotyped in-
dividually with the use of TaqMan or KASPar allelic discrimi-
nation on an ABI 7900HT (Applied Biosystems) according to the
manufacturer’s instructions. Of the 32 SNPs identified through
genome-wide association study efforts to be associated with
BMI (15), all but one (rs4836133 zinc finger protein 608) were
present in MDCS, and 4 proxies (r2 . 0.8) were used (rs6548238
THEM18; rs17782313 melanocortin 4 receptor; rs7498665 SH2B
adaptor protein 1; and rs10913469 SEC16 homolog B, endo-
plasmic reticulum export factor). The mean genotype call rate
was 97.1%, and all SNPs were in Hardy-Weinberg equilibrium
with P . 0.0016 (0.05/31). More details on the index and
proxy SNPs and genotype quality control are listed in Sup-
plemental Table 1.
GLACIER
DNA was extracted from peripheral white blood cells, and
genomic DNA was diluted to 4 ng/mL (16). Genotyping was
performed with the use of the MetaboChip array (Illumina
Inc.). Of the 32 BMI-associated SNPs (15), 7 proxies were
used that had an r2 . 0.8 (except rs1006353 mitochondrial
translational initiation factor 3, which had an r2 = 0.74):
rs10182181 Ras-associated protein Rap1; rs11165643 poly-
pyrimidine tract-binding protein 2; rs1421085 fat mass and
obesity-associated protein; rs7127684 ribosomal protein L27a;
rs2030323 brain-derived neurotrophic factor; rs17109256
neurexin 3; and rs1006353 mitochondrial translational initiation
factor 3. No proxy was available for the rs2890652 low-density
lipoprotein receptor-related protein 1B locus. Genotyping suc-
cess rate was .95%, and all 31 SNPs had a Hardy-Weinberg
equilibrium with P . 0.0016 (0.05/31). More details on the
index and proxy SNPs and genotype quality control are listed in
Supplemental Table 1.
Genetic risk score
To investigate aggregated genetic predisposition to obesity,
a genetic risk score (GRS) was constructed based on the 32 BMI-
associated loci. Missing genotypes were imputed in both cohorts
for participants with .60% of the 32 BMI-associated loci suc-
cessfully genotyped as previously described (17). In short, a
missing genotype is replaced with the mean value for that SNP
obtained from the fraction of participants with available geno-
typed data. Of the 32 BMI associated loci (15), rs4836133 zinc
finger protein 608 and rs2890652 lipoprotein receptor-related
protein 1B (or appropriate proxies) were not available in MDCS
and GLACIER, respectively. To facilitate comparisons and
subsequent meta-analyses of summary statistics, the GRSs were
constructed based on the remaining 30 BMI-associated loci in
both cohorts. A GRS was constructed for each participant by
summing up the risk alleles at each of the 30 loci assuming an
equal magnitude of effect at each locus. Genotypes were coded
as 0, 1, and 2, indicating the number of BMI-associated alleles
(15). In accordance with Qi et al. (7), a second GRS was con-
structed in which the contribution of each locus was weighted by
its previously reported main effect on BMI (15) before being
summarized into a weighted GRS (wGRS). To facilitate the in-
terpretation and comparisons of results, the wGRS was transformed
back to the same scale as the GRS by dividing each individual
wGRS by the maximum possible wGRS score (8.46) and
subsequently multiplying by 60 (the maximum number of risk
alleles) (18). Although it is appropriate to take into consider-
ation the contribution of each locus when constructing a GRS
for main-effect analyses by weighting with previously estab-
lished trait-specific effect sizes, there are thus far no good
solutions for how to appropriately account for locus-specific
contributions (i.e., main and interaction effects) in interaction
analyses. For this reason, we present the results for the un-
weighted GRS throughout, and the results from the wGRS are
presented in Supplemental Table 2. The results for both GRSs
are similar overall.
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Statistical analysis
Generalized linear equations were used to model the effects of
genotypes at each locus (coded as 0, 1, and 2) assuming an
additive effect of alleles. The SSB variable was categorized into
either 2 (seldom to low and medium to high) or 4 (seldom, low,
medium, and high) rank-ordered categories. This variable was
entered as a continuous variable in the models consistent with the
analyses reported by Qi et al. (7). All models were adjusted for
age-, sex-, and study-specific covariates as indicated. Interaction
models included the product term (GRS3 SSB or GRS3 ASB)
in addition to the marginal effect terms (GRS and SSB or ASB).
To account for potential confounding factors, a second model
was included that additionally adjusted for physical activity,
smoking, alcohol consumption, and total energy intake. Total
energy intake can be considered both a potential confounding
and mediating factor in these analyses. Excluding total energy
intake in sensitivity analyses did not materially change the re-
sults (data not shown) and was included as a covariate in the
presented lifestyle-adjusted models. To illustrate the interaction,
the association between the GRSs and BMI were analyzed by
stratifying and categorizing SSB intake, and the association of
SSB intake with BMI was stratified by cohort-specific quartiles
of the GRSs. For MDCS, all analyses were done with the use of
SPSS version 20.0 (IBM). SAS version 9.4 (SAS Institute) was
used for GLACIER.
Cohort-specific effect estimates from main and interaction
analyses and their respective variance estimates were combined
with the use of inverse variance-weighted fixed-effects meta-
analysis with the use of the metan command in Stata version 12
(StataCorp).
RESULTS
Marginal effect of SSBs, ASBs, and GRSs on BMI
Mean SSB daily intake in the overall cohort as well as within
each of the 4 categories of intake was similar between MDCS and
GLACIER (Table 1). In inverse variance-weighted fixed-effects
meta-analyses, each increment in SSB intake category was as-
sociated with a 0.18 (SE = 0.02) higher BMI (P = 1.7 3 10220;
n = 26,726): b = 0.19 (SE = 0.02) per SSB category in MDCS
(P = 1.2 3 10216; n = 21,824) and b = 0.05 (SE = 0.06) per SSB
category in GLACIER (P = 0.39; n = 4902). Analyses were ad-
justed for age-, sex-, and study-specific covariates and putative
confounders (alcohol consumption, smoking status, physical ac-
tivity, and total energy intake).
Each increment in category of ASB intake in MDCS was
significantly associated with a 0.64 (SE = 0.04) higher BMI
in MDCS (P = 3.9 3 10258; n = 21,824). The model was
adjusted for age-, sex-, and study-specific covariates and putative
TABLE 1
Participant characteristics in the Swedish MDCS and GLACIER cohort studies1
Characteristics
SSB intake2
P-trend3All Seldom Low Medium High
MDCS
Participants, n 21,824 9865 4261 3775 3923
Age, y 57.9 6 7.7 58.2 6 7.6 58.0 6 7.8 57.2 6 7.6 57.7 6 7.7 ,0.001
Sex, % women 62.1 63.1 66.2 63.5 53.8 ,0.001
BMI, kg/m2 25.7 6 3.8 25.6 6 3.8 25.5 6 3.7 25.7 6 3.9 26.1 6 4.0 ,0.001
Alcohol intake, g/d 10.9 6 12.7 11.3 6 13.1 10.2 6 11.1 11.1 6 11.8 10.5 6 13.3 ,0.001
Current smoking, % 27.7 28.6 25.1 26.9 29.0 ,0.001
Physically active, % 27.3 44.8 19.5 16.7 19.0 0.01
TEI, kJ/d 9460 6 2562 9025 6 2495 9393 6 2440 9686 6 2499 10,390 6 2650 ,0.001
SSB,2 servings/d 0.30 6 0.58 0.00 6 0.00 0.10 6 0.07 0.36 6 0.10 1.24 6 0.83 ,0.001
ASB, servings/d 0.04 6 0.21 0.04 6 0.22 0.04 6 0.19 0.05 6 0.20 0.05 6 0.19 0.002
GRS,4 effect alleles 27.6 6 3.4 27.7 6 3.4 27.6 6 3.4 27.5 6 3.4 27.5 6 3.4 0.13
GLACIER
Participants, n 4902 781 1017 2238 866
Age, y 49.0 6 8.6 51.0 6 8.1 51.2 6 7.9 47.8 6 8.7 47.7 6 8.8 ,0.0001
Sex, % women 62.0 77.5 69.0 57.3 51.9 ,0.0001
BMI, kg/m2 25.5 6 3.8 25.5 6 3.8 25.6 6 3.8 25.6 6 3.8 25.5 6 3.8 0.90
Alcohol intake, g/d 3.6 6 4.4 2.8 6 4.3 3.3 6 4.0 3.9 6 4.6 3.8 6 4.7 ,0.0001
Current smoking, % 21.6 25.1 23.2 19.5 22.1 0.01
Physically active, % 27.9 29.3 28.7 28.4 24.1 0.06
TEI, kJ/d 7455 6 2407 6376 6 1997 6787 6 2152 7649 6 2311 8703 6 2582 ,0.0001
SSB,2 servings/d 0.35 6 0.50 0.004 6 0.002 0.08 6 0.002 0.26 6 0.12 1.20 6 0.67 ,0.0001
GRS,4 effect alleles 27.5 6 3.4 27.5 6 3.2 27.6 6 3.4 27.5 6 3.4 27.4 6 3.4 0.36
1Data are means 6 SDs unless otherwise indicated, n = 26,726. ASB, artificially sweetened beverage; GLACIER,
Gene-Lifestyle Interactions and Complex Traits Involved in Elevated Disease Risk; GRS, genetic risk score; MDCS,
Malmo¨ Diet and Cancer Study; SSB, sugar-sweetened beverage; TEI, total energy intake.
2For MDCS, the seldom-intake group included participants who did not report any intake of SSB (or ASB) in the 7-d
menu booklet; the remaining participants were divided into a low-, medium-, and high-intake group based on tertiles of SSB (or
ASB) intake. For GLACIER, ranges of intake were applied to reflect the 4 groups in MDCS.
3ANOVA was used for continuous variables and the chi-square test for categorical variables.
4The GRS comprises 30 BMI-associated single-nucleotide polymorphisms with a theoretical range from 0 to 60.
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confounders as described previously. Adjusting additionally
for SSB intake did not materially change the results (data not
shown).
The GRS was significantly associated with BMI in both co-
horts [MDCS: b = 0.09 (SE = 0.01) per allele, P = 5.5 3 10229,
n = 21,824; GLACIER: b = 0.16 (SE = 0.02) per allele, P = 2.53
10223, n = 4902), analysis adjusted for age and sex. Weighting the
GRS by accounting for previously reported SNP-specific effect
estimates (15) yielded similar results [MDCS: b = 0.09 (SE =
0.01) per allele, P = 4.2 3 10210, n = 21,824; GLACIER: b =
0.13 (SE = 0.01) per allele, P = 2.5 3 10221, n = 4902)]. No
association between the GRS and SSB (or ASB) intake was ob-
served in either cohort (all P . 0.05). Cohort-specific marginal
effects for the individual 30 BMI-associated loci are presented in
Supplemental Table 3.
Interaction between GRS, SSB, and ASB intake on BMI
As shown in Table 2, there was a significant interaction be-
tween the GRS and SSB intake [defined either as 4 categories
(seldom, low, medium, and high intake) or dichotomized intake
(seldom-to-low compared with medium-to-high intake)] on BMI
in the pooled analysis. The magnitude of association of the GRS
(per 10-unit increment) with BMI was greater with each SSB
intake category increment (P-interaction = 0.02). Adjusting
additionally for putative-confounding lifestyle factors slightly
reduced the statistical significance of the observed interaction
(P-interaction = 0.03) (Table 2). In the lifestyle-adjusted pooled
analysis with dichotomized SSB intake, each 10-unit increment
of the GRS was associated with a mean 1.31 (SE = 0.11) higher
BMI in individuals reporting medium-to-high SSB intake (P =
1.2 3 10233), equivalent to 3.8 kg in weight for a person 1.70 m
tall. Among participants reporting seldom or low SSB intake,
each 10-unit increment of the GRS was associated with a 0.83
(SE = 0.09) higher BMI (P = 6.0 3 10221) or 2.4 kg in weight
for a person 1.70 m tall (P-interaction = 0.01) (Table 2). Similar
results were obtained with the wGRS (Supplemental Table 2).
The effect modifications of the association between SSB intake
(4 categories) and BMI by individual loci are presented in
Supplemental Table 4.
TABLE 2
The association with BMI per 10 effect alleles of the GRS stratified by SSB and ASB intake in MDCS and GLACIER1
Categories of intake
P-interaction
Categories of intake
P-interactionSeldom Low Medium High Seldom to low Medium to high
SSB
MDCS
Model 1 0.80 6 0.12 0.69 6 0.17 1.07 6 0.18 1.03 6 0.19 0.18 0.77 6 0.09 1.05 6 0.13 0.08
Model 2 0.83 6 0.11 0.68 6 0.16 1.06 6 0.18 1.03 6 0.19 0.28 0.79 6 0.09 1.05 6 0.13 0.12
GLACIER
Model 1 0.61 6 0.42 1.40 6 0.33 1.71 6 0.23 2.18 6 0.38 0.003 1.10 6 0.26 1.84 6 0.20 0.02
Model 2 0.57 6 0.42 1.40 6 0.33 1.73 6 0.23 2.30 6 0.37 0.002 1.09 6 0.26 1.88 6 0.19 0.01
Pooled cohorts2
Model 1 0.78 6 0.11 0.83 6 0.15 1.32 6 0.14 1.26 6 0.17 0.02 0.81 6 0.09 1.30 6 0.11 0.01
Model 2 0.82 6 0.11 0.82 6 0.15 1.32 6 0.14 1.28 6 0.17 0.03 0.83 6 0.09 1.31 6 0.11 0.01
ASB
MDCS
Model 1 0.85 6 0.08 0.89 6 0.48 0.95 6 0.41 0.94 6 0.56 0.63 0.81 6 0.08 0.97 6 0.33 0.58
Model 2 0.86 6 0.08 0.98 6 0.48 1.03 6 0.41 0.92 6 0.56 0.55 0.83 6 0.08 1.01 6 0.33 0.54
1Data are b-coefficients 6 SEs from linear regression models, n = 21,824 for MDCS and n = 4902 for GLACIER. Model 1 was adjusted for age-, sex-,
and cohort-specific covariates. MDCS was additionally adjusted for season and method. GLACIER was adjusted for the food-frequency questionnaire version
and the first 4 principal components. Model 2 includes Model 1 plus additional adjustments for physical activity, smoking status (current/former/never),
alcohol consumption, and total energy intake. ASB, artificially sweetened beverage; GLACIER, Gene-Lifestyle Interactions and Complex Traits Involved in
Elevated Disease Risk; GRS, genetic risk score; MDCS, Malmo¨ Diet and Cancer Study; SSB, sugar-sweetened beverage.
2Cohort-specific summary statistics were pooled with the use of an inverse variance-weighted, fixed-effects meta-analysis.
FIGURE 1 The difference in BMI (in kg/m2) associated with 1 incre-
ment in SSB intake (4 categories) in MDCS (n = 21,824), GLACIER (n =
4902), and a pooled analysis with the use of inverse variance-weighted fixed-
effect meta-analysis stratified by quartiles (Q1–Q4) of the GRS. Data are
b-coefficients and 95% CIs derived from linear regression models. Across
the quartiles of the GRS, a 1-increment increase in SSB intake was associ-
ated with 0.19 (95% CI: 0.11, 0.28), 0.13 (95% CI: 0.05, 0.22), 0.19 (95%
CI: 0.10, 0.29), and 0.22 (95% CI: 0.13, 0.31) increases in BMI in MDCS
and with 20.10 (95% CI: 20.31, 0.11), 20.08 (95% CI: 20.30, 0.15),
20.001 (95% CI: 20.23, 0.23), and 0.41 (95% CI: 0.16, 0.66) changes in
BMI in GLACIER. In the pooled analysis, 1 increment of SSB intake was
associated with 0.15 (95% CI: 0.08, 0.24), 0.11 (95% CI: 0.03, 0.19), 0.17
(95% CI: 0.08, 0.25), and 0.24 (95% CI: 0.15, 0.32) changes in BMI (all P,
0.01). The analysis was adjusted for age, sex, alcohol consumption, smoking
status, physical activity, total energy intake, and cohort-specific covariates.
GLACIER, Gene-Lifestyle Interactions and Complex Traits Involved in
Elevated Disease Risk; GRS, genetic risk score; MDCS, Malmo¨ Diet and
Cancer Study; SSB, sugar-sweetened beverage.
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As illustrated in Figure 1, in pooled analyses the magnitude
of the association between SSB intake (4 categories) and BMI
increased by GRS quartile: each SSB category increment was
associated with a 0.15 (SE = 0.04) higher BMI (P = 1.3 3 1024;
n = 6835) in the lowest quartile of the GRS compared with
a 0.24 (SE = 0.04) (P = 2.93 1028; n = 6766) higher BMI in the
highest quartile—the mean difference equivalent to 266 g in
weight for a person 1.70 m tall. Similar results were obtained
with the wGRS (Supplemental Figure 1).
ASB, defined either by 4 levels or dichotomized intake, did not
modify the association between the GRS and BMI in MDCS
(Table 2), with similar results observed for the wGRS (Supple-
mental Table 2).
DISCUSSION
In this study of 26,729 Swedish adults, we observed that the
magnitude of the association between SSB intake and BMI is
stronger in people genetically predisposed to obesity. Adjusting
for potential confounding lifestyle factors had no material impact
on these results. This finding is in agreement with the previously
published findings by Qi et al. (7).
Many epidemiologic studies, including randomized inter-
vention trials, have investigated the role of SSB in relation to
obesity, weight maintenance, and BMI and have found strong
associations with the consumption of SSB and increased BMI (1,
2, 19, 20). In contrast, a recent systematic review (21) concluded
that the role of SSB intake in obesity risk remains unclear because
many studies have not adjusted for total energy intake, which
makes it difficult to evaluate whether SSB intake contributes
to the risk of obesity beyond adding energy to the total diet.
However, no intervention trials passed the inclusion criteria and
were not included in the systematic review. The inconsistent
results might also partly be explained by individual genetic
susceptibility to obesity, as indicated by findings from 3 large US
cohorts (7) and further corroborated in 2 Swedish cohorts in this
study. Mean reported SSB intake SSB was similar between the
US and Swedish cohorts.
ASB intake was available in MDCS and is more strongly
associated with BMI than SSB. In accordance with Qi et al. (7),
the association is not modified by genetic predisposition to
BMI. The direction of causality between ASB and BMI has been
much debated (22), and it is likely because of reverse causality
that we observed such a strong association between ASB and
BMI. However, a recent study in humans suggests that the con-
stitution of the gut microbiota might mediate the association
between the consumption of artificial sweeteners and glucose
intolerance (23).
The main limitations of our study are the cross-sectional
design and that data on SSB and ASB intake are self-reported.
In addition, because the dietary assessment methods differ be-
tween the 2 cohorts, SSB intake could not be uniformly defined
across the 2 cohorts. Although the results are more pronounced
in GLACIER than MDCS, probably in part because of a larger
proportion of participants being labeled as seldom consumers
in MDCS as a result of the 7-d record period, the fact that we
observed similar trends in both cohorts reduces the possibil-
ity that any aspect of the diet assessment method could have
markedly confounded the results. The modified diet history
method in MDCS is very detailed and collects data on current
intake during the 7-d record period. The FFQ implemented in
GLACIER was designed to capture mean food frequencies dur-
ing the past year and is therefore more likely to capture habitual
diet intake. These methodologic differences in diet assessment
between MDCS and GLACIER result in differences in total
energy intake between the 2 cohorts that might partly explain why
we observed more of a dose-dependent effect modification in
GLACIER, which is in line with the results observed in the US
cohorts (7), whereas the results in MDCS indicate a threshold
effect (Table 2). It is, however, important to keep in mind that
seldom consumers in MDCS were individuals who did not report
any intake of SSB (or ASB) during the specific 7-d recording
period andmight thus harbor a certain degree of misclassification.
In the United States, high-fructose corn syrup, a mixture of free
glucose and fructose, is the caloric sweetener of sodas, whereas
sucrose (a disaccharide made up of glucose and fructose) is the
main sweetener used in Europe (19). It is still unclear whether
there is a difference in the obesogenic effects of high-fructose
corn syrup and sucrose, but the fact that we observed a similar
interaction between genetic susceptibility of obesity and SSB on
BMI in both the Swedish (albeit stronger in GLACIER than
MDCS) and US cohorts implies that the underlying mechanism is
independent of the type of sweetener.
Beyond the type of sweetener used in beverages, Sweden and
the United States differ in many cultural and lifestyle aspects.
This may even be true within Sweden given the great distance
between north and south (1572 km). However, the results in the
northern and southern Sweden cohorts are similar and in agree-
ment with the observations in the US cohorts, supporting the
original finding and suggesting that the interaction is likely to
be generalizable to other populations of European ancestry.
In summary, there is a growing body of evidence from epi-
demiologic studies in support of the health benefits associated
with an overall reduction in SSB consumption, and our results
support the initial finding indicating that this may be even more
relevant in people with a high genetic susceptibility to obesity.
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